Headache and Migraine

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 21, 2022.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 14, 2022.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is insomnia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 7, 2022.

Recent findings from a network meta-analysis suggest that high flow oxygen is more efficacious when compared with low flow oxygen for headache relief.

A narrative review revealed that cluster headache trials have been limited thus far, and that future trials should include novel outcome measures and adjusted end point timing.

A national survey showed in its findings that NSAIDs alone and dopamine receptor antagonists are used commonly for treating primary headache disorders in Canadian emergency departments.

No statistical differences were found between REN and the standard of care medications, in any of the effectiveness outcomes of pain single-treatment pain relief and pain freedom, nor in consistency of pain relief and pain freedom.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology, related to the recent 4th Annual International Congress on the Future of Neurology®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 23, 2022.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 23, 2022.

Migraine with aura is suggested as an independent risk factor for atrial fibrillation and that AFib-mediated cardioembolism may play a role with migraines, especially stroke association for some patients.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 16, 2022.

Approximately half of the respondents with a history of headache screened positive for migrainous headache by ID-migraine criterion with most reporting moderate to severe intensity headache.

In addition to headache, other COVID-19 symptoms such as anosmia, myalgia, and nausea or vomiting were associated with higher survival rates.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 9, 2022.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Treatment with rimegepant, an FDA-approved treatment for acute and preventative migraine, resulted in decreases of more than 30% in monthly butalbital prescription fill and reductions of more than 25% in mean milligrams dispensed.